Circulating Markers of Systemic Inflammation, Measured After Completion of Neoadjuvant Therapy, Associate With Response in Locally Advanced Rectal Cancer.

IF 3.2 2区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY
Ross K McMahon, Sean M O'Cathail, Colin W Steele, Harikrishnan S Nair, Jonathan J Platt, Donald C McMillan, Paul G Horgan, Campbell S Roxburgh
{"title":"Circulating Markers of Systemic Inflammation, Measured After Completion of Neoadjuvant Therapy, Associate With Response in Locally Advanced Rectal Cancer.","authors":"Ross K McMahon, Sean M O'Cathail, Colin W Steele, Harikrishnan S Nair, Jonathan J Platt, Donald C McMillan, Paul G Horgan, Campbell S Roxburgh","doi":"10.1097/DCR.0000000000003660","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The extent of neoadjuvant therapy response, prior to surgery, is an important prognosticator in locally advanced rectal cancer. A spectrum of response exists, with a dearth of reliable measurements. The host response to treatment remains unexplored. Within operable colorectal cancer, circulating markers of elevated systemic inflammation associate with poor survival. Studies have suggested that elevated pre-neoadjuvant inflammatory markers, including the modified Glasgow prognostic score and the neutrophil:lymphocyte ratio, associate with poorer response.</p><p><strong>Objective: </strong>This study aimed to comprehensively evaluate hematological markers of inflammation pre- and post-neoadjuvant therapy.</p><p><strong>Design: </strong>Longitudinal cohort study.</p><p><strong>Settings: </strong>Single health board from a prospectively maintained regional cancer database.</p><p><strong>Patients: </strong>Consecutive locally advanced rectal cancer patients who underwent curative-intent neoadjuvant therapy between; June 2016-July 2021.</p><p><strong>Main outcome measures: </strong>Elevated markers of the systemic inflammatory response pre- and post-neoadjuvant therapy.</p><p><strong>Results: </strong>A total of 278 patients (67.3% male, median age 65) were identified. A complete response (clinical or pathological complete response) was achieved in 27.34%, and good tumor regression was achieved in 37.05% (tumor regression grading 0-1). No pre-neoadjuvant marker associated with response or regression. Multivariate analysis of post-neoadjuvant variables revealed an elevated modified Glasgow prognostic score (OR 2.8, 95% CI: 1.22-6.41, p = 0.015), and an elevated carcinoembryonic-antigen (OR 4.09, 95% CI: 1.6-10.44, p = 0.003) independently associated with incomplete response. An elevated post-neoadjuvant modified Glasgow prognostic score (OR 2.14, 95% CI: 1.08-4.23, p = 0.029) also independently associated with poor tumor regression on multivariate analysis.</p><p><strong>Limitations: </strong>Retrospective design. Slight variation in the timing of post-neoadjuvant blood tests.</p><p><strong>Conclusions: </strong>We report that post-neoadjuvant modified Glasgow prognostic score associated with poorer response and regression, potentially indicating that radiation resistance is associated with the development of a protumor inflammatory environment. Further work is required to define the local intratumoral processes associated with response and their inter-relationship with systemic parameters. Ultimately, there may be a rationale for testing anti-inflammatory strategies in combination with radiotherapy as an option for optimizing treatment response. See Video Abstract.</p>","PeriodicalId":11299,"journal":{"name":"Diseases of the Colon & Rectum","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diseases of the Colon & Rectum","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/DCR.0000000000003660","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The extent of neoadjuvant therapy response, prior to surgery, is an important prognosticator in locally advanced rectal cancer. A spectrum of response exists, with a dearth of reliable measurements. The host response to treatment remains unexplored. Within operable colorectal cancer, circulating markers of elevated systemic inflammation associate with poor survival. Studies have suggested that elevated pre-neoadjuvant inflammatory markers, including the modified Glasgow prognostic score and the neutrophil:lymphocyte ratio, associate with poorer response.

Objective: This study aimed to comprehensively evaluate hematological markers of inflammation pre- and post-neoadjuvant therapy.

Design: Longitudinal cohort study.

Settings: Single health board from a prospectively maintained regional cancer database.

Patients: Consecutive locally advanced rectal cancer patients who underwent curative-intent neoadjuvant therapy between; June 2016-July 2021.

Main outcome measures: Elevated markers of the systemic inflammatory response pre- and post-neoadjuvant therapy.

Results: A total of 278 patients (67.3% male, median age 65) were identified. A complete response (clinical or pathological complete response) was achieved in 27.34%, and good tumor regression was achieved in 37.05% (tumor regression grading 0-1). No pre-neoadjuvant marker associated with response or regression. Multivariate analysis of post-neoadjuvant variables revealed an elevated modified Glasgow prognostic score (OR 2.8, 95% CI: 1.22-6.41, p = 0.015), and an elevated carcinoembryonic-antigen (OR 4.09, 95% CI: 1.6-10.44, p = 0.003) independently associated with incomplete response. An elevated post-neoadjuvant modified Glasgow prognostic score (OR 2.14, 95% CI: 1.08-4.23, p = 0.029) also independently associated with poor tumor regression on multivariate analysis.

Limitations: Retrospective design. Slight variation in the timing of post-neoadjuvant blood tests.

Conclusions: We report that post-neoadjuvant modified Glasgow prognostic score associated with poorer response and regression, potentially indicating that radiation resistance is associated with the development of a protumor inflammatory environment. Further work is required to define the local intratumoral processes associated with response and their inter-relationship with systemic parameters. Ultimately, there may be a rationale for testing anti-inflammatory strategies in combination with radiotherapy as an option for optimizing treatment response. See Video Abstract.

求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.50
自引率
7.70%
发文量
572
审稿时长
3-8 weeks
期刊介绍: Diseases of the Colon & Rectum (DCR) is the official journal of the American Society of Colon and Rectal Surgeons (ASCRS) dedicated to advancing the knowledge of intestinal disorders by providing a forum for communication amongst their members. The journal features timely editorials, original contributions and technical notes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信